Researchers reported that nintedanib was associated with higher costs for medications, medical visits, as well as a higher global cost compared with pirfenidone—both drugs used to treat idiopathic pulmonary fibrosis (IPF). These results were published in Respiratory Medicine and Research. IPF is a progressive and ultimately lethal lung disease of unknown cause. The prognosis remains extremely…
The drug nintedanib appears safe and well-tolerated in patients over 80 years of age with mild to moderate idiopathic pulmonary fibrosis (IPF), according to a study published in Respiration. IPF is a progressive, fibrosing interstitial lung disease of unknown cause. Its incidence increases with age, an unfortunate reality considering that many elderly individuals already have…
A large proportion of patients with idiopathic pulmonary fibrosis (IPF) who receive reduced-dose antifibrotic agents experience improved survival compared with cessation of treatment, according to the results of a retrospective analysis published in the journal Respiratory Medicine. It is well known that IPF is a severe interstitial lung disease for which 2 effective antifibrotic agents—nintedanib and…
Approximately one-third of patients are diagnosed with idiopathic pulmonary fibrosis (IPF) in Japan either during a routine health checkup or while undergoing an examination for another disease, while experiencing minimal or no respiratory symptoms, according to a new study published in Respiratory Medicine. In spite of being diagnosed at a relatively early stage of disease,…
Drugs targeting cyclin-dependent kinase (CDK) 4 and CDK6 can suppress the growth and survival of neoplastic mast cells, a new study published in Cancers found. Therefore, CDK4/CDK6 inhibitors could have curative potential in advanced systemic mastocytosis (SM), which is often resistant to drug treatment. The neoplastic mast cells, which are the hallmark of advanced SM,…
SH2 superbinder has significant antifibrotic effects, according to a new study published in Theranostics. The protein could therefore be used as a promising therapy for idiopathic pulmonary fibrosis (IPF), the authors of the study said. There is currently no effective treatment for IPF, so it is of great importance to developing new and better treatments…
A randomized, double-blind, placebo-controlled phase 2b study was terminated due to adverse events (AEs) and a lack of efficacy of BG00011, an anti-αvβ6 immunoglobulin G1 monoclonal antibody, as therapy for idiopathic pulmonary fibrosis (IPF), according to a study published in the American Journal of Respiratory and Critical Care Medicine. The study was carried out after…
Researchers discovered that patients with idiopathic pulmonary fibrosis (IPF) tend to have multiple comorbidities, which is associated with poorer survival, even in patients receiving antifibrotic therapy, as published in Respiratory Research. Patients with IPF often struggle with a high disease burden and experience pulmonary and extrapulmonary comorbidities. These commodities can be caused by risk factors…
Cudetaxestat is well tolerated and leads to no treatment-related serious adverse events when coadministered with pirfenidone or nintedanib in healthy volunteers, according to the results of a phase 1 clinical trial. There were also no drug-drug interactions with cudetaxestat plus pirfenidone or nintedanib. These results were presented at the American Thoracic Society 2022 International Conference.…
Researchers have discovered that radiomic features can be used to predict the therapeutic response of patients with idiopathic pulmonary fibrosis (IPF) to antifibrotic agents, as published in Diagnostics. IPF causes excessive fibrotic deposition in the lung parenchyma, eventually resulting in respiratory failure. This disease carries a poor prognosis, with mortality usually occurring within 5 years…
